Antithrombin exhibits anticoagulant effects on the emicizumab-based engineered bispecific antibody (NXT007)-mediated blood coagulation

Hemophilia A (HA) is one of the most common inherited bleeding disorders that results from a deficiency or defect in the protein factor (F)VIII. Repeated infusion of FVIII product has been carried out for bleeding-prophylaxis, which would reduce joint bleeding episodes and other hemorrhages. However, the treatment has some limitations including the formation of anti-FVIII alloantibodies (FVIII inhibitors) in 20–30 % of severe patients with HA (PwHA) [1] and frequent intravenous administration is responsible for a loss of adherence to the prophylaxis protocol.